Randomized Trial of Ofatumumab and Bendamustine versus Ofatumumab, Bendamustine and Bortezomib in previously untreated patients with highrisk follicular lymphoma: CALGB 50904 (Alliance)
- Citation:
- Cancer vol 125 (19) 3378-3389
- Year:
- 2019
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pmc-release
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- 9
- Parents:
- 2766
- Children:
- None
- Pharmas:
- GSK (Novartis)
- Grants:
- U10CA180821, U10CA180882, U10CA180833, U10CA180850, UG1CA189858
- Corr. Author:
- Authors:
- Kristie A. Blum Mei-Yin Polley Sin-Ho Jung Travis J. Dockter Sarah Anderson Eric D. Hsi Nina Wagner-Johnston Beth Christian Jim Atkins Bruce D. Cheson John P. Leonard Nancy L. Bartlett
- Networks:
- CAPITAL, LAPS-MD017, LAPS-MN026, LAPS-MO011, LAPS-OH007, NC002, NY018
- Study
- CALGB-50904
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords:
- Ofatumumab, bendamustine, bortezomib, follicular lymphoma